With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. | With an ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

The following is a summary of “Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus ...

Suggested remit: To appraise the clinical and cost effectiveness of Sasanlimab with BCG within its marketing authorisation for treating bladder cancer.

Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

BCG might be superior to sequential intravesical gemcitabine-docetaxel for reducing the risk of recurrence in patients with high-grade intermediate-risk NMIBC. Given the recent global shortage of ...

Oral presentation provides update from QUILT-3.032 on durable complete responses to ANKTIVA ® plus BCG in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) with or ...

ANKTIVA was approved by the FDA in 2024 for BCG-unresponsive non-muscle invasive bladder cancer CIS with or without papillary tumors. For more information, visit ImmunityBio.com (Founder’s ...